Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

Core Insights - Immuneering Corporation will report its third quarter 2025 financial results and share case studies from a Phase 2a study of atebimetinib in combination with FOLFIRINOX for first-line pancreatic cancer patients on November 12, 2025 [1] Company Overview - Immuneering is a clinical-stage oncology company focused on developing a new category of cancer medicines known as Deep Cyclic Inhibitors [3] - The lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK aimed at improving durability and tolerability for MAPK pathway-driven tumors, including pancreatic cancers [3] - Currently, atebimetinib is in a Phase 2a trial targeting advanced solid tumors, including pancreatic cancer [3]